Dexcom Q4 2023 revenue $1.03B, up 27%; GAAP EPS $0.62; FY2024 guidance $4.15-4.35B

DEXCOM INC

2023-FY EPS reported $1.30 revenue$3,622,300,000

Q4 2023 revenue $1.03B (+27% YoY); GAAP operating income $216.9M (21.0% margin).
GAAP net income $256.3M ($0.62 diluted EPS) vs $91.8M ($0.22) in Q4 2022.
Full-year 2023 revenue $3.62B (+24% YoY); GAAP operating margin 16.5% (+310 bps).
2024 guidance: revenue $4.15-4.35B (16-21% organic growth); non-GAAP op margin ~20%.
Submitted Stelo glucose sensor for type 2 diabetes (non-insulin) and direct-to-watch feature to FDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

DEXCOM INC updated its the quarter and year ended December 31, 2023 guidance (reaffirmed).

Period: the quarter and year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 8, 2024, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023 and certain other information.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

DEXCOM INC filing history →

Source: SEC EDGAR

accession 0001093557-24-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.